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PATENTING THE HUMAN BODY: THE




I. INTRODUCTIONLISBETH Ceriani wants to know her risk for ovarian cancer.' Her
physician told her that she could have a genetic predisposition to
the disease, especially after being diagnosed with cancer in both of
her breasts.2 The single mother, who is covered by a Medicaid insurance
program for low-income citizens, sent her blood work to the only labora-
tory in the United States that is authorized to look at her genes and tell
her if any mutations predispose her to the disease.3 The problem is that
this laboratory will not accept her insurance, and she cannot afford the
$3,000 test out-of-pocket. 4
When faced with a similar problem, Rumi Limary switched insurance
providers and finally obtained an analysis of her breast and ovarian genes
from the exclusive laboratory, which informed her that she had a "genetic
variant of uncertain significance." 5 The laboratory does not look for all
known mutations when analyzing breast and ovarian cancer genes, but at
the same time, it is effectively blocking anyone else from looking.6 While
Ms. Limary is willing to pay for more testing, no one can provide it be-
cause analyzing mutations in Ms. Limary's genes can bring liability for
patent infringement.7
* J.D. Candidate, SMU Dedman School of Law, 2011. I thank my husband, Kyle,
for introducing me to this intriguing topic and supporting me along the way.
1. Complaint at 10, Ass'n for Molecular Pathology v. U.S. Patent & Trademark Of-
fice, 669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09 Civ. 4515), 2007 WL 1343027 (including a
list of similarly situated plaintiffs); see also John Schwartz, Cancer Patients Sue Testing
Company and Government Over Cancer Gene, N.Y. TIMES, May 13, 2009, at A16 (describ-
ing the predicament of another plaintiff). Genae Girard joined as a plaintiff when she was
told she could not independently confirm her results from a Myriad laboratory, indicating
she had a predisposition to ovarian cancer and thereby suggesting the need to get her
ovaries taken out. Schwartz, supra.








Nearly twenty percent of human genes are patented under United
States law.8 A large portion of these patents cover genes related to
human health-almost half of human genes related to cancers, including
the breast and ovarian cancer genes from the real-life examples above,
are included in this list.9 Proponents of gene patenting point to statutes
and case law to show an absence of any government restrictions-Con-
gress has had opportunities to ban or limit gene patenting but currently
has failed to do so.1o The patent protection for gene sequences is neces-
sary, they say, to provide incentives for companies heavily investing in
research." If these companies are not able to recoup their expenses
through royalties and license fees, their investments are unlikely to ever
pay off.1 2 But opponents of gene patenting point to the development of
monopolies that can harm the most vulnerable members of society-the
sick. 13 The most obvious concerns voiced by critics of gene patenting
include limited access to testing and diagnosis, no availability of confir-
mation or verification of test results, and no competition regarding the
price of diagnostic testing. 14 Finally, critics are concerned that patent
holders of genetic material inappropriately interfere with the physician-
patient relationship by marketing their diagnostic tests and analysis di-
rectly to the patients.15
Part II of this Comment explains how gene patents developed under
the U.S. patent law system, including the creation of the patent statutes
and early case law addressing patentability of organic materials. Part III
discusses the major recent developments and controversies in gene-pat-
ent law, including the most recent lawsuits and legislative actions. It also
details the most recently suggested and most practicable solutions to the
gene-patent dilemma in the United States. Finally, Part IV analyzes the
8. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human Gen-
ome, 310 Sci. 239, 239 (2005).
9. Id. at 240.
10. Genomic Research and Diagnostic Accessibility Act of 2002, H.R. 3967, 107th
Cong. (2002), available at http://www.govtrack.us/congress/bill.xpd?bill=hl07-3967 [herein-
after Genomic Research and Diagnostic Accessibility Act]; Turna Ray, Recognizing Far-
Reaching Implications of ACLU Anti-Gene Patent Case, Court Denies Myriad's Motion to
Dismiss, PHARMACOGENOMIcs REP., Nov. 4, 2009, http://www.genomeweb.com/dxpgx/rec-
ognizing-far-reaching-implications-aclu-anti-gene-patent-case-court-denies-my.
11. Eric D. Zard, Patentability of Human Genetic Information: Exploring Ethical Di-
lemmas Within the Patent Office and Biotechnology's Clash with the Public Good, 6 U. ST.
THOMAs L.J. 486, 487 (2009).
12. Id. at 487, 509.
13. Jon F. Merz, Disease Gene Patents: Overcoming Unethical Constraints on Clinical
Laboratory Medicine, 45 CLINICAL CHEMISTRY 324, 326 (1999).
14. David H. Ledbetter, Gene patenting and licensing: the role of academic researchers
and advocacy groups, 10 GENETICS IN MED. 314, 314 (2008).
15. Merz, supra note 13, at 326. A more recent example of such suggested interfer-
ence is the BRACAnalysis diagnostic test, exclusively administered by Myriad Genetics,
with more information about the test available at http://www.bracnow.com (last visited
Aug. 11, 2010). The website provides a quiz to help potential patients determine if genetic
testing is "right" for them, a link to the television commercial for the test, and a database
of physicians who the patient can visit to have the physician order the BRACAnalysis test
from the Myriad Genetics laboratory. Id.
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possible changes meant to address the gene-patent debate, weighs the ad-
vantages and disadvantages, and analyzes the likelihood of these changes
being successful in the immediate future.
II. THE DEVELOPMENT OF HUMAN GENES AND THE
RIGHTS TO PATENT THEM
A. AN INTRODUCTION TO PATENT LAW IN THE UNITED STATES
The U.S. law governing patent protection has a history spanning centu-
ries, enacted by the first Congress in 1790.16 Congress created such pat-
ent legislation based on constitutionally granted authority "to promote
the progress of science and useful arts."17 Under the subsequently passed
legislation in 1793, anyone who applied was granted patent protection as
long as they complied with the formal filing requirements.18 This simplis-
tic process of obtaining patent protection continued until 1836, when
Congress made its first major changes to the patent laws by introducing
the Patent Office and granting it authority to not only consider patent
applications but also refuse to grant patent protection if certain require-
ments were not met. 19 Numerous amendments and more than a century
later, Congress again revisited patent laws in a major way when it recodi-
fied Title 35 of the United States Code and created the patent laws in
effect today.20
Under the most recent codification of the U.S. patent laws in 35 U.S.C.
§ 101, "[w]hoever invents or discovers any new and useful process, ma-
chine, manufacture, or composition of matter, or any new and useful im-
provement thereof, may obtain a patent thereof, subject to the conditions
and requirements of this title." 21 Those conditions and requirements in-
dicate that the subject matter of the patent must have (1) utility, 2 2 (2)
novelty,23 (3) non-obviousness, 24 (4) a written description,25 and (5) en-
ablement.26 According to legislative history and later court interpreta-
tions, this language is meant to have a broad reach and cover "anything
under the sun that is made by man" as long as specific requirements of
Title 35 are satisfied.27 The subject matter satisfies the utility require-
16. S. REP. No. 82-1979, at 2396 (1952) ("When the first Congress met, one of its very
first items of business was the consideration of patents and copyright, and the first patent
bill was H.R. 10 of the First Congress.").
17. Id.; see also U.S. CONST. art. I, § 8 ("The Congress shall have power to . . . promote
the progress of science and useful arts, by securing for limited times to authors and inven-
tors the exclusive right to their respective writings and discoveries.").
18. S. REP. No. 82-1979, at 2397.
19. Id.
20. Id.; see 35 U.S.C. § 101 (2006).
21. § 101 (emphasis added).
22. Id.
23. Id. § 102 (2006).
24. Id. § 103 (2006).
25. Id. § 112 (2006).
26. Id.
27. S. REP. No. 82-1979, at 2399 (1952); Diamond v. Chakrabarty, 447 U.S. 303, 308
(1980) (interpreting 35 U.S.C. § 101 by stating that "[i]n choosing such expansive terms as
2010] 1321
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ment if it is not only new but also "useful." 28 The subject matter satisfies
the novelty requirement only if it was not used in the United States prior
to the patent applicant's invention of it, was not written about in United
States or foreign publications prior to the invention, and was not pat-
ented in a foreign country within a year of the patent application in the
United States.29 The subject matter does not satisfy the non-obviousness
requirement when the difference between it and the subject from which it
is being invented (what was known before) would be obvious to someone
skilled in that subject. 30 The written description and enablement require-
ments call for the patent applicant to describe the invented subject matter
in detail and enable anyone skilled in the industry to which the invention
pertains to be able to recreate it. 3 1
B. THE ROAD TO PATENTING LIVING THINGS
The basic concept of genetics has existed for centuries, originating from
observing traits passed from parents to their children.32 Genetics as they
are understood today, however, did not take shape until the twentieth
century, which started with the discovery of the very first gene and con-
cluded as the Human Genome Project was on the road to identifying
every gene in the human DNA. 3 3 The Human Genome Project was fi-
nally completed in 2003, with 23,688 genes identified. 34 While most scien-
tists struggle to define the term "gene" even today, a definition relied on
by a basic medical textbook refers to it as a "physical and functional unit
of heredity, which carries information from one generation to the next."35
The surge to obtain patent protection for these newly discovered genes
is a result of several major developments of the late twentieth century,
including the economic hardship of the 1970s and 1980s.3 6 In response to
this economic downturn, Congress sought to help domestic technology
industries by making significant changes to the patent system.37 Specifi-
'manufacture' and 'composition of matter,' modified by the comprehensive 'any,' Congress
plainly contemplated that the patent laws would be given wide scope.").
28. § 101.
29. Id. § 102.
30. Id. § 103(a).
31. Id. § 112.
32. Cindy Pham Lorentz, Eric D. Wieben, Ayalew Tefferi, David A.H. Whiteman &
Gordon W. Dewald, Primer on Medical Genomics Part I: History of Genetics and Sequenc-
ing of the Human Genome, 77 MAYO CLINIC PROc. 773, 773 (2002); Eric D. Wieben, Pri-
mer on Medical Genomics Part VII: The Evolving Concept of the Gene, 78 MAYO CLINIC
PROC. 580, 580 (2003) (crediting Aristotle with first taking note that "children often inherit
anything that is peculiar in their parents").
33. Lorentz, Wieben, Tefferi, Whiteman & Dewald, supra note 32, at 774; Zard, supra
note 11, at 486, 490.
34. About the Human Genome Project, Human Genome Project Information, http://
www.ornl.gov/sci/techresources/HumanGenome/project/about.shtml (last visited Aug. 12,
2010); Jensen & Murray, supra note 8, at 239.
35. Wieben, supra note 32, at 580, 587.
36. Roger D. Klein, Gene patents and genetic testing in the United States, 25 NATURE
BIOTECHNOLOGY 989, 989 (2007).
37. Id.
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cally, Congress passed legislation aiming to incentivize universities to fi-
nancially gain from their government-sponsored scientific research. 38
The Bayh-Dole Act, passed in 1980, was not created to benefit the gov-
ernment directly; however, the government indirectly profited through
the increased taxes paid by the beneficiaries of the Act.39 The Act al-
lowed universities to obtain patent protection on inventions that their re-
searchers created using federal funding, and universities were also further
encouraged to commercialize these inventions "for the public good."40
The Act, however, did not specifically restrict universities in their re-
search and patenting practices, except for the limitation requiring them to
prioritize partnerships with U.S. businesses, especially smaller compa-
nies. 4 1 The Act did not require the universities that were receiving the
government funding to make their subsequent inventions publically avail-
able.4 2 As a result of the Act, the government increased its contributions
to scientific research at the university level, and patents acquired by uni-
versities increased from 264 in 1979 to 3,291 in 2002.43
Another development that played a significant role in the gene-patent
surge is twentieth century jurisprudence.44 In 1911, a New York district
court first faced an organic substance patenting dilemma when it consid-
ered a patent on an extract from an animal gland.45 While the substance
existed in nature, the court upheld the patentability of the substance be-
cause "no one had yet produced the free base."46 The court explained
that this purified substance was patentable because:
[The patent holder] was the first to make it available for any use by
removing it from the other gland-tissue in which it was found, and,
while it is of course possible logically to call this a purification of the
principle, it became for every practical purpose a new thing commer-
cially and therapeutically.47
"But, even if it were merely an extracted product without change, there is
no rule that such products are not patentable."48
This landmark decision led the way for other courts to also declare that
organic matter may be patentable as long as it is in purified form and
38. Id.; 35 U.S.C. § 200 (2006) ("It is the policy and objective of the Congress to use
the patent system to promote the utilization of inventions arising from federally supported
research or development . . . .").




43. Klein, supra note 36, at 989.
44. See, e.g., Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980); Parker v. Flook, 437
U.S. 584, 594 (1978); Gottschalk v. Benson, 409 U.S. 63 (1972); In re Bergstrom, 427 F.2d
1394 (C.C.P.A. 1970).
45. Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 97-98 (C.C.S.D.N.Y. 1911).
46. Id. at 103, 113-114.




other patent law requirements are also satisfied.4 9 Today, the United
States Patent and Trademark Office uses the Parke-Davis & Co. decision
to justify granting patents on genes, explaining that patenting of genetic
material "follows well-established principles, and is not a new practice."50
One possible roadblock to granting patent protection on purified or-
ganic substances is the argument that these substances do not qualify as
patentable under 35 U.S.C. § 102 because they are not novel.51 The
Court of Customs and Patent Appeals was faced with this issue in 1970,
when the lower patent courts both denied patent protection for composi-
tions of matter that had been isolated and purified. 5 2 The substances
were derived from human and animal genital glands, but before they
reached the state at which they were patented, they were treated with
many substances including ether and phosphate, were allowed to evapo-
rate and turn to powder, and finally were turned into crystals.53 In this
purified form, the substances could lower rabbit blood pressure-a qual-
ity not present in the substances in a less purified form. 5 4 The Court of
Customs and Patent Appeals reversed the denial of patent protection in
this case because it found the substances to be not naturally occurring-
the pure form of the substances, as it was described in the patent, did not
exist in nature.55 Because pure minerals are different from less pure min-
erals, the court concluded the pure minerals described in the patent appli-
cation were novel, or "new" as compared to the less pure form.56
Therefore, the substances were patentable and the lower courts should
not have denied the patent applications.5 7
Later decisions by the United States Supreme Court, however, made
these earlier distinctions less clear.58 When faced with nature and patents
in Parker v. Flook, the Court stated that the laws of nature cannot be
patented because those laws are not the type of discoveries contemplated
by the writers of the patent statutes.5 9 The Court compared the laws of
nature to Isaac Newton's discovery of gravity-even before Newton an-
nounced his discovery, the law of gravity already existed in nature.6o The
Court explained that making the discovery did not give Newton the right
to patent it and exclude others because the phenomenon of gravity had
49. Lauren M. Nowierski, A Defense of Patenting Human Gene Sequences Under U.S.
Law: Support for the Patenting of Isolated and Purified Substances, 26 CARDOZo ARTS &
ENT. L.J. 473, 483 (2008).
50. 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001) (notice).
51. 35 U.S.C. § 102 (2006); In re Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970).
52. In re Bergstrom, 427 F.2d at 1396-98.
53. Id. at 1396.
54. Id. at 1397.
55. Id. at 1401.
56. Id. at 1401-02 (explaining that "pure materials necessarily differ from less pure or
impure materials and, if the latter are the only ones existing and available as a standard of
reference, as seems to be the situation here, perforce the 'pure' materials are 'new' with
respect to them").
57. Id. at 1402.
58. See, e.g., Parker v. Flook, 437 U.S. 584 (1978).
59. Id. at 596.
60. Id. at 593 n.15.
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always existed.61 The only way a law of nature can be subject to a patent
is when the patent applicant finds some way to use this law of nature to
achieve a new and useful result. 6 2
Two years later, the Court had a chance to elaborate on its Parker dicta
in a decision that set the stage for patenting of human genes.63 The Court
once again delved into the patentability of the laws of nature, but this
new decision allowing patenting of human-made microorganisms is what
helped propel the gene-patent surge.64 In Diamond v. Chakrabarty, the
Court considered whether a live bacterium that was genetically engi-
neered qualified under the language of 35 U.S.C. § 101 as patentable sub-
ject matter.65 Chakrabarty was a microbiologist who made the bacterium
that could break down crude oil, a quality not present in naturally occur-
ring bacteria and therefore made this creation a potential asset when
dealing with oil spills, and also extremely financially valuable. 66 When
Chakrabarty applied for a patent on the bacterium he was initially re-
jected-the patent examiner concluded that microorganisms are not pat-
entable subject matter because they are products of nature, and
generally, living things are not patentable under 35 U.S.C. § 101.67 The
Supreme Court granted certiorari after patent appellate courts, analyzing
Chakrabarty's application, split on the way living organisms are to be
treated under 35 U.S.C. § 101.68
The slim majority of the Court interpreted Congress as having intended
§ 101 to have a broad application, covering even what Congress could not
contemplate at the time of the statute's creation.69 Instead of distinguish-
ing the case on living organism grounds, the Court said the focus should
be on whether the subject matter is naturally occurring. 70 Something oc-
curring naturally, such as a newly discovered mineral or a new plant
found in the wild, could not be patented under the Court's interpretation
of 35 U.S.C. § 101.71 In this case, however, no bacterium naturally occur-
ring in nature had the same characteristics as the bacterium Chakrabarty
engineered-that is why the bacterium was patentable subject matter, ac-
cording to the Court. 72 The Court concluded its analysis by emphasizing
that it is up to Congress to clarify, if it sees fit, whether living things or
genetically engineered organisms should be exempted from the patent
61. Id. (quoting P. ROSENBERG, PATENT LAW FUNDAMENTALS § 4, at 13 (1975)) (ex-
plaining that this reasoning is 'founded upon the proposition that in granting patent
rights, the public must not be deprived of any rights that it theretofore freely enjoyed."'
62. Id. at 591.
63. See Diamond v. Chakrabarty, 447 U.S. 303, 315 (1980).
64. Klein, supra note 36, at 989; see also Diamond, 447 U.S. at 309, 318.
65. Diamond, 447 U.S. at 305.
66. Id.
67. Id. at 305-06.
68. Id. at 306.
69. Id. at 315-16.
70. Id. at 309-10.
71. Id. at 309.
72. Id. at 310.
2010] 1325
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statute.73 Until Congress chooses to do so, the Court declined to make
the tough judgment calls on matters of policy or competing values that it
found would be involved in such an analysis. 74
III. CHAKRABARTY REPERCUSSIONS AND RECENT
DEVELOPMENTS IN GENE PATENT LAW
A. THE BREWING BRCA GENE PATENT CONTROVERSY
Today, nearly twenty percent of human genes are patented under U.S.
law.75 While the majority of genes still remain unclaimed, the ones to
which rights have been asserted under patent law are primarily genes as-
sociated with human health.76 For example, patents are claimed on dia-
betes and obesity genes, as well as almost half of the genes related to
cancers.' 7 As new diseases are discovered, patents are asserted on the
viruses as well.' 8 In addition to these genes themselves being patented
subject matter, patent holders also assert claims to numerous ways the
genes may be used and ways in which they are manifested, including in
diagnostic procedures. 79 For example, one of the most patented genes is
a tumor suppression gene, which is claimed in twenty separate patents.80
Under U.S. patent law, owners of gene patents are not required to
share their rights with anyone.8 1 However, many patent holders choose
to grant licenses on their patents in order to make profits or continuing
royalties from others' use.8 2 Patent holders may limit such licenses by the
scope of use-for example, allowing licensees only to research either di-
agnostic or therapeutic properties of the gene. 83 The majority of gene
patent holders do not have a problem issuing licenses to diagnostic labo-
ratories. 84 For example, the patent holders for the cystic fibrosis gene,
the Hospital for Sick Children and the University of Michigan, have cho-
sen to grant nonexclusive licenses for laboratories diagnosing the dis-
73. Id. at 318.
74. Id. at 317. When the petitioner suggested multiple negative implications of grant-
ing a patent on a microorganism, the Court responded that it is up to Congress to make the
more serious policy decisions it was being asked to make: "Whatever [the validity of nega-
tive consequences of the Court's ruling], the contentions now pressed on us should be
addressed to the political branches of the Government . . . ." Id.
75. Jensen & Murray, supra note 8, at 239.
76. Id. at 240.
77. Id.
78. Scientists Race to Patent SARS Virus: Efforts to Claim Property Rights Spark Ethi-
cal Debate, MSNBC (Nov. 4, 2003, 7:09 PM), http://www.msnbc.msn.com/id/3076748/
[hereinafter Scientists Race to Patent SARS Virus].
79. Jensen & Murray, supra note 8, at 239.
80. Id.
81. Ledbetter, supra note 14, at 316.
82. Id.
83. Id.
84. Jon F. Merz & Mildred K. Cho, What Are Gene Patents and Why Are People Wor-
ried About Them?, 8 COMMUNITy GENETIcs 203, 205 (2005) ("[Tlhe owners of the over-
whelming majority of issued gene patents have not aggressively enforced their rights
against clinical molecular diagnostics laboratories.").
[Vol. 631326
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ease.85 As a result, the disease may now be diagnosed by a variety of
tests and kits,86 allowing for potential price reductions and second
opinions.87
However, one major patent holder chose to exclude others from diag-
nosing mutations of a gene it held a patent on,8 8 thereby exacerbating the
already brewing controversy 89 over the issuance of gene patents. Myriad
Genetics, Inc.,90 a U.S.-based company, chose a path "unprecedented in
the field of genetic testing," deciding to exercise its power to monopolize
the diagnostic, as well as all other uses, of the breast and ovarian cancer
genes (BRCA1 and BRCA2).91 Consequently, all non-Myriad-owned
laboratories diagnosing a predisposition to these cancers by looking for
mutations in the patient's genes were estopped from performing any
more tests.92 The lawsuit that followed has been heralded by some as the
"beginning of the end" to gene patenting.93
Gene-patent litigation has mostly focused on patent infringement, ex-
ceeding license scope, and appealing the denial of patent applications by
the patent office. 94 According to a 2007 study, gene patent litigation
peaked in 1997-1998 with a high of thirteen pending gene-patent lawsuits
at one time.95 But that number has since dropped off to one or two law-
85. Ledbetter, supra note 14, at 317.
86. Id.
87. Id. at 315.
88. Gert Matthijs, The European Opposition Against the BRCA Gene Patents, 5 FA-
MILIAL CANCER 95, 95-102 (2006).
89. Michael Crichton, Patenting Life, N.Y. TIMEs, Feb. 13, 2007, at A23 (noting that
"[ylou, or someone you love, may die because of a gene patent that should never have
been granted in the first place"); Anna Salleh, Researchers in Patent Catch-22, ABC Sca.
(Jan. 28, 2005), http://www.abc.net.au/science/news/stories/sl290889.htm ("Patenting of
SARS genes renewed the debate over the ethics of gene patenting with opponents seeing
patenting as a commerciali[z]ation of life."); Jon F. Merz, Disease Gene Patents: Overcom-
ing Unethical Constraints on Clinical Laboratory Medicine, 45 CLINICAL CHEMISTRY 324,
324 (1999). The author presents a fictitious scenario in which the Vatican purchases the
exclusive license to the Down syndrome gene and announces its plan to enforce a monop-
oly, effectively eliminating early fetus tests of the disease in the United States. Id. The
author explains his scenario as a cautionary tale:
The good news is that the Church will not prevent prenatal screening for
devastating genetic anomalies that often lead to abortion of an affected fetus,
a test that is the standard of care throughout the US. The bad news is that
there is nothing in law that would prevent the license above from being nego-
tiated, and little to prevent the licensee from preventing others from practic-
ing the patented test.
Id.
90. On the company website, Myriad Genetics is described as "committed to improve
patient healthcare through the commercialization of predictive medicine, personalized
medicine, and prognostic medicine products." MYRIAD, http://www.myriad.com/ (last vis-
ited Jul. 23, 2010).
91. Matthijs, supra note 88, at 95.
92. Timothy Caulfield, Tania Bubela & C.J. Murdoch, Myriad and the Mass Media:
The Covering of a Gene Patent Controversy, 9 GENETICS MED. 850, 850 (2007).
93. Ray, supra note 10.
94. Christopher M. Holman, Learning from Litigation: What Can Lawsuits Teach Us
About the Role of Human Gene Patents in Research and Innovation?, 18 KAN. J.L. & PUB.




suits per year.96 In May 2009, another gene-patent complaint was added
to this list.9 7 But in an unprecedented move,98 the American Civil Liber-
ties Union, physicians and physician groups, and patients joined in a law-
suit to challenge the constitutionality of Myriad's BRCA1 and BRCA2
genes.99 Specifically, the plaintiffs alleged that the patenting of human
genes and the process of comparing genes to look for a mutation is
against the principle that laws of nature and products of nature cannot be
patented.100 The second, and more unusual, claim was that the patents
on human genes violate the plaintiffs' First Amendment rights. 10' And
perhaps to emphasize the gravity of their allegations, the plaintiffs added
the U.S. Patent and Trademark Office to the list of defendants in this
action.102
The complaint alleged an injury to the patients by way of restricted
access to gene mutation testing to determine their predisposition to
breast and ovarian cancers.103 This allegation is based not only on Myr-
iad Genetics's ownership of the patent but also on the fact that Myriad
Genetics made the decision not to license the patents broadly to other
physician facilities and laboratories.104 The patent prevents anyone other
than Myriad Genetics from analyzing the patient's BRCA1 and BRCA2
genes-either to determine a predisposition to the two cancers or to ver-
ify Myriad's laboratory results independently. 05 For example, the
problems created by this limited access are evident in Myriad's refusal to
accept certain insurances to pay for the testing, leaving one of the plain-
tiffs who could not independently pay for the testing with no alterna-
tives.106 Additionally, a plaintiff who received a test result stating
"genetic variant of uncertain significance" is unable to obtain any addi-
tional analysis on her gene, even though Myriad Genetics does not test
for all known mutations. 07
According to the complaint, researchers in the 1990s first began look-
ing for a gene whose mutation would indicate a predisposition to breast
and ovarian cancers.108 Collectively, the researchers concluded that this
specific gene was located on human chromosome 17.109 A research team
associated with Myriad Genetics "sequenced" this gene, named BRCA1,
96. Id.
97. Complaint, supra note 1, at 10.
98. Ray, supra note 10.
99. Complaint, supra note 1, at 1-2.
100. Id. at 18.
101. Id. at 19.
102. Id. at 1.
103. Id. at 2.
104. Id.
105. Id.
106. Complaint, supra note 1, at 10.
107. Schwartz, supra note 1; see also Complaint, supra note 1, at 11.
108. Complaint, supra note 1, at 12.
109. Id.
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and applied for the patent at issue in this litigation. 110 Subsequently,
Myriad's research team sequenced another gene whose mutation also
showed the predisposition-named BRCA2.111 The genes in their iso-
lated form have the same qualities as the genes inside the human body.
Nevertheless, the United States Patent and Trademark Office allows pat-
enting of "isolated and purified" human genes.112 Because the patent of-
fice allows not only the patenting of the laws of nature but also the
thought process of comparing one gene to another and noting its natu-
rally occurring mutations, the plaintiffs allege in their complaint against
Myriad Genetics and the patent office not only a violation of the patent
statute, 35 U.S.C. § 101, but also the constitutional violation on the free-
dom of thought. 13
The defendants filed a motion to dismiss based on multiple assertions,
including lack of standing, sovereign immunity bar by the patent office,
and failure to state a constitutional claim.114 Additionally, defendants
asked to dismiss because there was no case or controversy-the plaintiffs
had not taken any action, such as infringement, and there was no re-
sponse by the defendants on which the plaintiffs could sue."15
Underscoring the importance of the rights at stake, the district court
denied the defendants' motion to dismiss." 6 The court focused on a con-
stitutional grievance being at issue, and stated that "[t]he novel circum-
stances presented by this action against the USPTO, the absence of any
remedy provided in the Patent Act, and the important constitutional
rights the Plaintiffs seek to vindicate establish subject jurisdiction.""'7
The court also concluded that the complaint was sufficient to allege a
constitutional challenge because patenting laws of nature, which the com-
plaint alleged to be the gene mutations and the genes themselves, vio-
lated the freedom of thought." 8
Even before the trial court denied the defendants' motion to dismiss,
the plaintiffs had already filed a motion for summary judgment.119 The
motion reiterated the points raised in the initial complaint, emphasizing
in particular the unconstitutionality of a patent that restricts comparing
two genes (both products of nature) and thinking that one has an abnor-
110. Id.; see Facts About Genome Sequencing, HUMAN GENOME PROJECT INFORMA-
TION, http://www.ornl.gov/sci/techresources/HumanGenome/faq/seqfacts.shtml#whatis
(last visited Oct. 15, 2010).
111. Complaint, supra note 1, at 18.
112. Id. at 19.
113. Id.
114. Defendant United States Patent & Trademark Office's Memorandum of Law in
Support of Motion to Dismiss, Ass'n for Molecular Pathology v. U.S. Patent & Trademark
Office, 669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09 Civ 4515).
115. Id. at 6-7.
116. Ass'n for Molecular Pathology, 669 F. Supp. 2d at 370.
117. Id. at 383.
118. Id. at 398.
119. Plaintiffs' Memorandum of Law in Support for Motion for Summary Judgment at
1, Ass'n for Molecular Pathology, 669 F. Supp. 2d 365 (No. 09 Civ. 4515).
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mality as compared to the other.120 Attorneys for the American Civil
Liberties Union, one of the plaintiffs in this lawsuit, have indicated that
by filing this complaint they aim to eradicate the patenting of human
genes altogether, beyond just the BRCA1 and BRCA2.121 Specifically,
one of the attorneys was quoted as saying "[w]e hope this [court] chal-
lenge is the beginning of the end to patents on genes, which limit scien-
tific research, learning, and the free flow of information . . . . No one
should be able to patent a part of the human body."122
The trial court granted the plaintiffs' motion for summary judgment,
invalidating not only the processes of comparing genes but more impor-
tantly Myriad's patents on both the genes themselves. 123 The court, how-
ever, dismissed the plaintiffs' First Amendment claims because of the
constitutional avoidance doctrine-requiring courts not to reach unneces-
sary constitutional questions.124 The court noted that if the Federal Cir-
cuit or the Supreme Court upholds this decision, it would serve the
plaintiffs' desired purpose of invalidating all current gene patents.125
However, Myriad Genetics promptly appealed the ruling to the Federal
Circuit.126
Although not directly pertaining to gene patents, Prometheus Labora-
tories, Inc. v. Mayo Collaborative Services is a timely case involving a pat-
ent claim that is very similar to Myriad's patent on comparing genes and
finding mutations.127 Prometheus's patent at issue in the case covers a
method for determining an effect of a drug on the human body, in order
to treat gastrointestinal and nongastrointestinal autoimmune disorders.128
Specifically, the patent covers two steps: (1) administering a particular
medication to a patient and (2) observing the drug's effects as it metabo-
lizes in the patient's body, which allows the patent holder to change the
medication dosage to better suit the patient. 129 Mayo Collaborative Ser-
vices used Prometheus's patented method for a period of time, after
which it announced it was going to administer its own test.130 Prometheus
responded with a lawsuit against Mayo for patent infringement, and in
response Mayo filed its own lawsuit, claiming the method patented by
Prometheus was not patentable subject matter under 35 U.S.C. § 101.131
120. Id. at 19.
121. Ray, supra note 10.
122. Id.
123. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 234-38 (S.D.N.Y. 2010).
124. Id. at 237-38.
125. Id. at 238.
126. Turna Ray, Myriad to Appeal District Court's Decision in Anti-Gene Patenting
Lawsuit, PHARMACOGENOMICs REP. (June 23, 2010), http://www.genomeweb.com/dxpgx/
myriad-appeal-district-courts-decision-anti-gene-patenting-lawsuit.
127. 581 F.3d 1336 (Fed. Cir. 2009), vacated, No. 09-490 (U.S. June 29, 2010), available
at 2010 WL 2571881 (remanding the case to the Federal Circuit for reconsideration).
128. Id. at 1339.
129. Id.
130. Id. at 1340.
131. Id.
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The district court agreed with Mayo and invalidated the patent, causing
an appeal by Prometheus and a subsequent decision by the Federal
Circuit. 132
The court applied a new test, articulated in its earlier decision,133 to
determine that the process was indeed patent-eligible under 35 U.S.C.
§ 101.134 Under this new test, a patent applicant can patent a process
"either by showing that his claim is tied to a particular machine, or by
showing that his claim transforms an article."135 Additionally, the trans-
formation "must impose meaningful limits on the claim's scope to impart
patent-eligibility" and the transformation must be significant.136
The court concluded that the patent in this case falls squarely "within
the realm of patentable subject matter" because the human body under-
goes a transformation when metabolizing the drug, therefore satisfying
the first prong of the Bilski analysis.'3 7 More importantly, the court rea-
soned that despite metabolization being a natural process, the process
could still be subject to a patent on the basis that administering the drug
is not a natural process.138 Moreover, determining whether the metabo-
lized drug levels are too high also involves the unnatural process requir-
ing the patent holder to "extract the metabolites from a bodily sample
and determine their concentration."13 9 Because administering the drug
and determining its metabolized state are transformative and not natural
processes, the court concluded that the patented process was valid under
35 U.S.C. § 101.140 Finally, the court concluded that the final step of the
patented process-the determination of whether too much or too little
drug was administered-is patentable but only because it is part of the
entire claim.141 Significantly, the court stated in dicta that the mental
determination-of whether enough of the drug was administered-by it-
self is not patentable subject matter.142
The court distinguished this part of the ruling from an earlier case, In re
Grams, in which it found a somewhat similar process nonpatentable.143
In that case, the court invalidated a patent on:
(1) performing a clinical test on individuals and (2) based on the data
from that test, determining if an abnormality existed and determin-
132. Id. at 1341.
133. In re Bilski, 545 F.3d 943, 954 (Fed. Cir. 2008), aff'd, Bilski v. Kappos, 130 S. Ct.
3218 (2010).
134. Prometheus, 581 F.3d at 1342.
135. In re Bilski, 545 F.3d at 961. The Supreme Court has since held that while this test
is a valid analysis, it is not the sole test to determine whether a process is patentable.
Instead, the Court suggested the lower courts should be more flexible with emerging tech-
nology. Bilski, 130 S. Ct. at 3221-23.
136. In re Bilski, at 961-62.
137. Prometheus, 581 F.3d at 1346-47.
138. Id. at 1346.
139. Id. at 1347.
140. Id.





ing possible causes of any abnormality by using an algorithm. We
found that this process was not drawn to patentable subject matter
because the essence of the claimed process was the mathematical al-
gorithm, rather than any transformation of the tested individuals.
More specifically, the Grams process was unpatentable because "it
was merely an algorithm combined with a data-gathering step," i.e.,
performing a clinical test.144
This decision to validate the patented process of administering a drug
and determining its level in the body after it has been metabolized is not
settled law at this point. The Supreme Court granted certiorari and re-
manded the case back to the Federal Circuit to consider it again in light
of the Bilski opinion, which affirmed the Federal Circuit decision but con-
cluded that the machine and transformation test (which was also applied
in Prometheus) is not the sole test to evaluate what is a patentable pro-
cess. 145 By remanding Prometheus, the Supreme Court declined an op-
portunity to elaborate on Bilski and thereby clarify what exactly it takes
to patent a process. While not directly addressing gene patents, the Pro-
metheus decision on remand, and on a potential appeal to the Supreme
Court, may be the first concrete answer to how courts view process pat-
enting within the biomedical field.
B. OTHER POTENTIAL AVENUES To LIMIT OR STOP GENE PATENTING
While the Supreme Court has not directly addressed the patentability
of genes, it might not have to if other branches of the government take
decisive steps to address the current controversy. First, Congress can sim-
ply change the current laws to address gene patenting and either elimi-
nate the practice altogether or limit it to prevent diagnostic monopolies
and give patients more options. 146 Also, the patent office can take steps
to limit the future granting of patents by excluding patents on diagnostic
and comparing methods, 147 such as some of the Myriad patents. Other
agencies have also expressed their desire for an overhaul, either through
recommendations or even direct competition with the private commu-
nity.148 And as a last resort, critics of gene patents have suggested off-
shoring of diagnostic tests to countries where gene-patent holders will not
enforce a restriction-an option that upon further exploration is not
likely to be successful. 149
1. Congress can amend current patent laws to ban all gene patents
The most obvious way to solve the gene-patent dilemma is to amend 35
U.S.C. § 101 in a way that would protect the rights of patients and doctors
while still incentivizing research in the field. Not surprisingly, some mem-
144. Id.
145. Bilski, 130 S. Ct. at 3221.
146. See infra Part II.B.1-2.
147. See infra Part II.B.3.
148. See infra Part II.B.4-5.
149. See infra Part II.B.4.
1332 [Vol. 63
Patenting the Human Body
bers of the 107th Congress attempted to do just that when they proposed
the Genomic Research and Diagnostic Accessibility Act of 2002.150 The
Act was introduced "[t]o amend title 35, United States Code, to provide
for noninfringing uses of patents on genetic sequence information for
purposes of research and genetic diagnostic testing, and to require public
disclosure of such information in certain patent applications."1 5  How-
ever, the proposed Act stalled in the early stages of the 107th Con-
gress. 152 Today, there is renewed talk of exempting patient care and
research from gene patent infringement liability.' 53 But the opposition
from the biotechnology sector is strong, and it appears any concrete steps
toward relaxation of gene patenting are far off in the future.154
2. Congress can pass legislation to amend patent laws and exclude gene
diagnostic methods from patent protection
In Europe, critics have suggested that while patenting the isolated gene
is allowed, patenting a diagnostic process such as comparing genes to find
mutations is outside the scope of European patent law. 55 The patent
statute has an exception, stating that "European patents shall not be
granted in respect of . .. methods for treatment of the human or animal
body by surgery or therapy and diagnostic methods practi[c]ed on the
human or animal body."156 This provision was first introduced to prevent
patenting medical procedures, such as surgeries, and therefore not in-
fringe on physicians' ability to aid their patients.'57 While recent devel-
opments suggest that the European Patent Office has not extended this
exception to block gene patenting entirely,158 it is perhaps an indication
of what is to come in terms of gene-patenting exceptions. A commenta-
tor has suggested that "a broader interpretation of [this statutory excep-
tion] is a way to avoid monopolies on the use of a genetic sequence for
diagnostic purposes in humans, without interfering with patent protection
of other genetic applications, including the development of therapeu-
tics."1 5 9 United States patent laws also have a limitation on patent in-
fringement for medical procedures, added in 1999 at 35 U.S.C. § 287:
150. Genomic Research and Diagnostic Accessibility Act, supra note 10.
151. Id.
152. Id.
153. Ray, supra note 10.
154. Id.
155. Matthijs, supra note 88, at 99-100.
156. Convention on the Grant of European Patents, art. 53(c), Oct. 5, 1973, 13 I.L.M.
270 (as amended by Revision Act of Nov. 29, 2000) (emphasis added), available at http://
www.epo.org/patents/law/legal-texts/epc.htmlEuropean Patent Convention [hereinafter
European Patents Convention].
157. Matthijs, supra note 88, at 100.
158. Turna Ray, EPO's Decision to Amend Myriad's BRCAl IP May Create More Un-
certainty for Euro Labs, PHARMACOGENOMics REP. (Dec. 3, 2008) http://www.genomeweb.
com/dxpgx/epos-decision-amend-myriad's-brcal-ip-may-create-more-uncertainty-euro-
labs.
159. Matthijs, supra note 88, at 100.
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(c)(1) With respect to a medical practitioner's performance of a med-
ical activity that constitutes an infringement . .. ,the [infringement]
provisions . . . of this title shall not apply against the medical practi-
tioner or against a related health care entity with respect to such
medical activity.
(2) For the purposes of this subsection:
(A) the term "medical activity" means the performance of a medi-
cal or surgical procedure on a body, but shall not include (i) the use
of a patented machine, manufacture, or composition of matter in vio-
lation of such patent, (ii) the practice of a patented use of a composi-
tion of matter in violation of such patent, or (iii) the practice of a
process in violation of a biotechnology patent.160
While this provision clearly excludes use of diagnostic testing, it has
been suggested that the statute needs to be amended to include the use of
gene patents for diagnostic purposes.161 By not allowing physicians to
choose the method of diagnosis for their patients, physicians are pre-
vented from looking out for the best interests of their patients.162
3. While the patent office cannot act against current statute, it can take
steps to limit granting of patents that have negative impact
on patient care
The United States Patent and Trademark Office is also unlikely to take
any steps to limit the issuance or application of gene patents. When re-
sponding to public comments on the patentability of genes, the patent
office made it very clear that it perceived gene patenting as ratified both
by Congress in passage of 35 U.S.C. § 101 and by the jurisprudence inter-
preting the statute.163 In response to criticism that genes are found in
nature, the patent office responded:
A patent on a gene covers the isolated and purified gene but does
not cover the gene as it occurs in nature. Thus, the concern that a
person whose body 'includes' a patented gene could infringe the pat-
ent is misfounded. The body does not contain the patented, isolated
and purified gene because genes in the body are not in the patented,
isolated and purified form.164
The patent office also clarified that it would not take it upon itself to
make any changes to patent laws in order to address the controversy sur-
rounding gene patents.165 Responding to a recommendation that the pat-
ent office "should 'allow for others to learn from and improve the
invention,"' the patent office clarified that the statute is very clear, and it
authorizes a patent holder to exclude anyone else from utilizing the pat-
160. 35 U.S.C. § 287 (2006).
161. Merz, supra note 13, at 328.
162. Id.
163. Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001).
164. Id.
165. Id. at 1096.
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ent.1 6 6 Therefore, it is up to Congress to make exceptions, if any.167
Commentators have also suggested that the patent office should more
closely scrutinize the granting of patents on genes.168 They have identi-
fied several potential issues that may result in granting patents that are
too broad, including financial incentives, expertise, and time manage-
ment.169 The most troubling is the compensation system relied on by the
patent examiners; they are rewarded with a bonus for granting or denying
a patent and therefore are encouraged to move patent applications
through rapidly.170 The potential for lack of scrutiny is exacerbated be-
cause denied applications are more often appealed, making it less prob-
lematic to grant the applications in order to avoid the long appeals
process.17' Another suggested fix is making sure gene-patent applica-
tions are considered by examiners with at least some level of expertise in
the biotechnology area because otherwise the patent applicants can get
away with overly broad applications that an untrained eye will not scruti-
nize as closely.172 And finally, commentators suggest that patent examin-
ers should spend more than the average eighteen hours on patent
applications with more significant social value.'73 This will require the
patent office to make a judgment call as to which patent applications are
of greater importance to society and how much more damaging a broad
patent in one area will be than in another.174
4. Other governmental agencies have taken steps that show their desire
for an overhaul to the status quo
The Department of Health and Human Services has also weighed in on
the gene-patent controversy by having the National Institutes of Health
(NIH) issue recommendations to gene-patent holders.175 After soliciting
public comments, NIH adopted a final version of the "Best Practices for
the Licensing of Genomic Inventions: Final Notice."176 After soliciting
public comments on the recommendations, NIH was criticized for setting
bad policy precedent by focusing on only one specialized sector of patent
law.' 77 But NIH responded that this special treatment of gene patenting
was justified because of the amount of controversy gene patenting had
created and because of the government's strong financial involvement
166. Id.
167. Id.
168. Jordan Paradise, Lori Andrews & Timothy Holbrook, Patents on Human Genes:







175. See generally Best Practices for the Licensing of Genomic Inventions, 70 Fed. Reg.





and contributions to genetic research through the Bayh-Dole Act. 178
NIH first addressed the gene-patenting practice in general, suggesting
that patents on genes should rarely be sought when the substance discov-
ered requires little development and research to reach its full potential
utility and commercial value. 179 NIH also addressed licensing practices,
suggesting that "[a] non-exclusive licensing approach favors and facili-
tates making broad enabling technologies and research uses of inventions
widely available and accessible to the scientific community." 80 When
specifically addressing the licensing of gene patents, NIH suggested a par-
ticular licensing approach that would limit licenses within therapeutic re-
search but would grant nonexclusive licensing for diagnostic tests and the
discovery of still-unknown mutations of a gene. 181
NIH emphasized that government funding recipients and the biotech-
nology community as a whole should find these recommendations helpful
in considering the consequences of their licensing practices on public
health.182 However, these recommendations have no binding authority
within the patent-holder community, and it is not clear how many patent
holders abide by the recommendations (if any).183
5. The government is joining the race to patent genes and thereby
prevent more private monopolies
The world outbreak of the SARS virus revealed another way the gov-
ernment could act to protect the public against potential monopolizing of
gene patents.184 Once the genetic sequence of the virus was decoded by
multitudes of scientists around the world, everyone joined the race to pat-
ent every part of the virus.185 The United States government, via the
Centers of Disease Control and Prevention (CDC), joined the race to
patent the SARS gene along with pharmaceutical companies and private
researchers. 186 In what some referred to as a "pre-emptive strike,"' 87 the
government decided to join the race to patent the virus with "[t]he whole
purpose of the patent [being] to prevent folks from controlling the tech-
nology .... This is being done to give the industry and other researchers
reasonable access to the samples."' 88 This action by the government,
whether an act of desperation or innovation, could set a new trend in
patent law, and create a solution for the future victims of yet-undiscov-
178. Id.





184. Gene Patents and the Public Good: A Race to Claim Patents on the SARS Virus
Raises Questions About the Patent System's Ability to Cope with Genomics, 423 NATURE
207, 207 (2003) [hereinafter Gene Patents].
185. Scientists Race to Patent SARS Virus, supra note 78.
186. Id.
187. Gene Patents, supra note 184.
188. Scientists Race to Patent SARS Virus, supra note 78.
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ered diseases. This action by the government is especially appealing be-
cause new genetic discoveries are being made at a rapid pace.189
6. Offshoring diagnostic testing to countries where gene patent holders
do not enforce their rights
At first glance, another path to avoid gene-patent infringement is to go
outside the United States to conduct any potentially infringing re-
search.190 While the European Patent Office first granted Myriad Genet-
ics a complete patent on diagnosing mutations in the BRCA1 gene, this
patent has since undergone major scrutiny and has been revoked but later
reinstated in modified form.191 Specifically, after Myriad Genetics first
received patent protection for the BRCA1 gene in Europe, critics, includ-
ing governments, organizations, and other professionals, were initially
successful in getting the entire patent revoked.192 But Myriad Genetics
appealed this decision, and eight years later the patent was partially rein-
stated-allowing about sixty percent of possible BRCA mutations to be
covered by the gene patent while excluding the rest.193 Consequently,
European diagnostic laboratories are now unsure on how to proceed
without running into infringement liability.19 4 But with some mutation-
diagnosing not off limits, the laboratories appear in a better position to
bargain for licenses than laboratories in the United States-where all di-
agnostic procedures infringe on the patent. 195
Despite this setback by the European Patent Office, companies that
hold gene patents in the United States, such as Myriad, cannot enforce
their patents unless they are consistently paying maintenance fees to the
governments of the other countries where they want the patents en-
forced.196 Therefore, offshoring diagnostic tests, where infringement
claims cannot reach, is still a possibility, especially in Europe with so
many countries sharing borders.
189. See Andy Coghlan, Gene discoveries could crack bone disease, NEW SCIENTIST
(Apr. 30, 2008, 3:30 PM), http://www.newscientist.com/article/dn13808-gene-discoveries-
could-crack-bone-disease.htmlhaasFormId=46aa9eea-8158-4b87-8d70-3994c2albd64&
haasPage=0 (stating that scientists from the U.K. and Iceland discovered gene mutations
that may lead to osteoporosis, clearing the way for diagnostic screening for predisposi-
tions); Genes Reveal "Biological Ageing," BBC NEWS (Feb. 8, 2010, 12:23 AM), http://
news.bbc.co.uk/2/hi/healthl8500761.stm (stating that British researchers discovered the ge-
netic variance that determines whether someone is predisposed to earlier ageing); Prema-
ture Birth Gene Clue Found, BBC NEWS (Feb. 5, 2010, 11:56 PM), http://news.bbc.co.uk/2/
hi/health/8498712.stm (stating that the National Institutes of Healthy study discovered the
DNA variants in mothers and babies that lead to premature births).
190. Christopher M. Holman, Learning from Litigation: What Can Lawsuits Teach us
About the Role of Human Gene Patents in Research and Innovation?, 18 KAN. J.L. & PUB.
PoL'Y 215, 220 (2009).
191. Ray, supra note 10.
192. Matthijs, supra note 88, at 95.






IV. WHICH OF THE POSSIBLE SOLUTIONS OFFER THE BEST
PROTECTION FOR PUBLIC HEALTH WHILE RETAINING THE
INTEGRITY OF THE PATENT SYSTEM?
A. THE POSSIBLE ROLE OF THE JUDICIAL SYSTEM, AT LEAST IN THE
IMMEDIATE FUTURE, APPEARS TO BE LIMITED
The patent litigation pending in lower courts today does not appear to
present a clear opportunity for the Supreme Court to weigh in on the
gene-patenting debate in the immediate future. When weighing in on the
Bilski decision, the Court affirmed the Federal Circuit and declined to
"define further what constitutes a patentable 'process."' 197 It does not
appear that this decision will affect the nearly twenty percent of gene
patents already granted. 198
A closer look at the Supreme Court's stance on the issue may be ob-
tained when the Federal Circuit decides Prometheus on remand, and the
potential appeal to the Supreme Court. 199 While the Prometheus claims
also do not directly address the patentability of genes, the case does pre-
sent issues resembling Myriad Genetics's patent claims on the BRCA1
and BRCA2 genes. Specifically, the patents in both cases lay claim to a
process that involves analyzing an extract of the human body and making
a mental determination based on this observation. 200 In Prometheus, the
mental process patented concerns the mental determination of an effect a
medication has on the human body once it is metabolized. 201 Similarly,
Myriad Genetics's patented method concerns the mental process of look-
ing at two genes, mentally noting any differences, and the mental thought
that a difference indicates a mutation and therefore a predisposition to
cancer. 202 However, as the Federal Circuit explained in Prometheus, the
major distinction between the patent in Prometheus and patents similar
to Myriad Genetics's is that the process in Prometheus is only one part of
a larger patent process claim.203 In the comparable Myriad Genetics
claim, the granted patent solely concerns the mental analysis.204
The earliest that the Supreme Court can weigh in directly on the gene-
patent controversy is if the Myriad Genetics litigation moves all the way
up on appeal. However, even if the case moves up, it is still unlikely that
the court will choose to hear this potential appeal not only because of the
small number of appeals it accepts annually, but more importantly be-
cause of the position it took in Chakrabarty, where it declared that similar
decisions of policy are better left for the legislature. 205 However, the
197. Bilski v. Kappos, 130 S. Ct. 3218, 3222 (2010).
198. Jensen & Murray, supra note 8, at 239.
199. Prometheus Labs v. Mayo Collaborative Servs., 581 F.3d 1336 (Fed. Cir. 2009),
vacated, 130 S. Ct. 3543 (remanding to the Federal Circuit for reconsideration).
200. Id.; Complaint, supra note 1, at 23.
201. Prometheus, 581 F.3d at 1348.
202. Complaint, supra note 1, at 23.
203. Prometheus, 581 F.3d at 1348.
204. Complaint, supra note 1, at 23.
205. Diamond v. Chakrabarty, 447 U.S. 303, 317 (1980).
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Court may be interested in the Myriad litigation because of the years of
controversy surrounding genes patents and the lack of any action by the
other branches of the government. Also, the Court might be interested in
the freedom of thought challenge in the novel First Amendment claim the
plaintiffs presented-a way to challenge a gene patent that the courts had
not yet seen.206 But because the complaint is still in the early stages, it
may be years before it reaches a final resolution.
If this case does reach the Supreme Court, there is a possibility that the
Court may invalidate the patent on the process of comparing two genes
and noting differences. As the court in Prometheus pointed out, by refer-
ring to its earlier In re Grams decision, a mental process by itself is not
patentable subject matter. 207 If the Supreme Court chooses to adopt the
In re Grams reasoning, at least a portion of Myriad Genetics's patents
may be invalidated. 208
The more complex issue, and one the Court is less likely to address
directly, is whether the genes themselves are subject to patenting. While
the Myriad Genetics case challenges the gene patent itself, Supreme
Court precedent indicates the Court is unlikely to create any new prohibi-
tions on gene patenting. First, in deciding Chakrabarty, the Court was
very clear that it wanted Congress to make the tough policy decisions
involved in patenting organic material, and the Court refused the argu-
ment for an outright judicial ban on such patenting.209 Because of this
strong stance, the Court is unlikely to go back on its own reasoning and
ban all gene patenting-it is more likely to suggest that it is up to the
legislature to take such action. Additionally, in Chakrabarty the Court
upheld the patent on the microorganism because it was not naturally oc-
curring,210 and based on that reasoning the Court may also accept the
gene-patent proponents' argument that the patented genes are also not
naturally occurring-isolated and purified human genes are not found in
nature.211 Therefore, opponents of gene patents are likely to have to find
206. See generally Ray, supra note 10.
207. Prometheus, 581 F.3d at 1348.
208. Complaint, supra note 1, at 23 ("What is patented is ... thinking 'there are
differences."').
209. Chakrabarty, 447 U.S. at 317. When called upon to end the patenting of micro-
organisms, the Court responded that:
[t]he choice we are urged to make is a matter of high policy for resolution
within the legislative process after the kind of investigation, examination, and
study that legislative bodies can provide and courts cannot. That process in-
volves the balancing of competing values and interests, which in our democ-
racy system is the business of elected representatives.
Id.
210. Id. at 305.
211. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001); In re
Bergstrom, 166 U.S.P.Q. 256, 261-62 (1970). The court concluded that the substances in
question were "new," even though there were isolated and purified form of substances
existing in nature, reasoning:
At the outset we would observe that what appellants claim-pure PGEsub2
and pure PGEsub3-is not "naturally occurring." Those compounds, as far
as the record establishes, do not exist in nature in pure form, and appellants
have neither merely discovered, nor claimed sufficiently broadly to encom-
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other avenues if they want a complete halt to gene patenting.
B. CONGRESSIONAL ACTION To LIMIT GENE PATENTING, NOT BAN
THEM ALTOGETHER, IS A MORE PLAUSIBLE OPTION THAT CAN
BALANCE PUBLIC HEALTH WIH ECONOMIC REALITIES
As per the Supreme Court's suggestion in the Chakrabarty decision, 212
congressional legislation is the most obvious avenue for any major
changes to the United States patent statutes. Nevertheless, judging by its
lack of action thus far, it is extremely unlikely that Congress will invali-
date patents on human genes entirely. First, Congress has had several
opportunities to take specific action but has chosen not to follow
through.213 If such legislation has previously been opposed by the bio-
technology industry, that opposition is unlikely to fade with more gene
patents being granted and more investments being made. With nearly
twenty percent of genes already subject to patents, it appears Congress
has missed a timely opportunity to intervene.
A more plausible option includes a limit on gene patents-not com-
plete eradication. 214 While the U.S. patent law does not have an excep-
tion that bans patents on treatment and diagnostic methods, a limited
exception from liability does exist for "medical activity" practiced on the
human body.215 Experts have suggested that such an exception, if ex-
panded to include diagnosis and testing, is the most reasonable solution
that the biotechnology industry can also accept.216 European patent law
has a slightly broader exception, 217 but it also has not yet been expanded
to specifically include diagnostic methods involving the analysis of human
genes.218 An exception that only includes diagnostic and testing methods
is more likely to be accepted by the biotechnology industry because it
would not be as costly a loss as having gene patents invalidated across the
board.
As the Department of Health and Human Services explained in its rec-
ommendations on gene-patent practice, the need for a patent is not as
significant when not much more investment and research is needed to
develop the patent.219 Therefore, a patent on a gene itself might be
needed to justify the investment to find a drug and therefore recoup re-
search costs. However, a patent on the diagnostic method is not as neces-
pass, what has previously existed in fact in nature's storehouse, albeit un-
known, or what has previously been known to exist.
Id.
212. Chakrabarty, 447 U.S. at 317.
213. See Genomic Research and Diagnostic Accessibility Act, supra note 10; see also
Ray, supra note 10.
214. See Matthijs, supra note 88, at 101.
215. 35 U.S.C. § 287 (2006).
216. Matthijs, supra note 88, at 100.
217. European Patents Convention, supra note 10, art. 53(c).
218. Matthijs, supra note 88, at 100.
219. Best Practices for the Licensing of Genomic Inventions, 70 Fed. Reg. 18413, 18415
(Apr. 11, 2005) (final notice).
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sary because once the diagnostic method is known, not much more
investment is needed and there is not as much potential for future pay-
out.2 2 0 Because a much smaller amount of potential proceeds are at
stake in such a solution, it might have more of a chance to pass in
Congress.
Additionally, the Bayh-Dole Act justifies such a step by Congress be-
cause the Act was one of the main reasons gene patenting became preva-
lent in the first place.221 It only makes sense that the public reaps at least
some benefits-benefits to public health in this case-from genetic re-
search that is supported with public funds. Additionally, Congress would
be justified because several agencies have already taken steps to show
their concern with the recent developments in gene patenting. First, the
CDC has indicated how concerned it is with the growing monopolization
of gene patents by taking action during the SARS outbreak.222 Fearing
that a private company will monopolize the gene and not allow anyone
else access, the CDC itself applied for the patent.223 Because new genetic
links and mutations are still being discovered at a fast pace, 224 this should
have sent a strong message to Congress on the urgent need for reform.
Moreover, the Department of Health and Human Services has also in-
dicated its desire to limit the scope of gene patents. While the Depart-
ment cannot bind the Patent Office or the patent applicants or patent
holders, it has addressed the gene-patent controversy through recommen-
dations that suggest gene patents should not be granted to include diag-
nostic and testing methods.225
In its recommendations, the Department acknowledged that it is sin-
gling out just one specific area of patent law in need of limitations, but it
also explained that limits are especially important in this area because of
the amount of controversy gene patenting has caused. 226 As a second
and less restrictive alternative, the Department recommended fewer re-
strictions on licensing of gene patents by the patent holders, especially
when it comes to uses not involving development of therapeutics.227 But
because the Department can only issue recommendations, without any
220. Id.; Merz, supra note 13, at 328.
221. See Best Practices for the Licensing of Genomic Inventions, 70 Fed. Reg. 18413,
18413 (Apr. 11, 2005) (final notice) (suggesting that the National Institutes of Health can
make suggestions to gene patent holders based on the reasoning that the government is
such a big financial contributor to genetic research through the Bayh-Dole Act); see also
Ledbetter, supra note 14, at 315.
222. Scientists Race to Patent SARS Virus, supra note 78.
223. Id.
224. See sources cited supra note 189.
225. Best Practices for the Licensing of Genomic Inventions, 70 Fed. Reg. 18413, 18415
(Apr. 11, 2005) (final notice).
226. Id. at 18413.
227. Id. at 18415. The Department gave an example of a scenario calling for loosening
of license restrictions:
For example, patent claims to gene sequences could be licensed exclusively in
a limited field of use drawn to development of antisense molecules in thera-
peutic protocols. Independent of such exclusive consideration, the same in-
tellectual property rights could be licensed non-exclusively for diagnostic
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authority to bind, the problems it aimed to address still persist today.228
V. CONCLUSION
This comment has examined the development of gene patent law in the
United States. It explained the early development of gene patent law,
and recapped and analyzed the most recent developments in the area,
including a host of potential resolutions to the ongoing policy debate. Fi-
nally, the Comment analyzed the possible resolutions and the potential
for the end of gene patenting in the United States, as well as the more
likely limitations on gene patenting.
The numerous ways2 2 9 in which different governmental bodies have at-
tempted to address the patenting of organic material, and human genes in
particular, should be more than enough indication to Congress that bind-
ing action is needed to address the controversy. From the Supreme
Court's implicit invitation in Chakrabarty for elected officials to address
policy issues relating to patents on organic material to the CDC's attempt
to patent genes so that no one else can gain a monopoly, an overhaul, or
at least an exception for diagnostics and testing, is long overdue in United
States patent law.
testing or as research probe to study gene expression under varying physio-
logical conditions.
Id.
228. See generally Complaint, supra note 1. Patenting the process of analyzing human
genes to note mutations and therefore determine predisposition to breast or ovarian cancer
is the type of process the recommendations suggested should no longer be patented.
229. See Best Practices for the Licensing of Genomic Inventions, 70 Fed. Reg. 18413,
18415 (Apr. 11, 2005) (final notice); Genomic Research and Diagnostic Accessibility Act,
supra note 10; Scientists Race to Patent SARS Virus, supra note 78; see also Diamond v.
Chakrabarty, 447 U.S. 303, 317 (1980) (calling on Congress to address the complex issues
relating to patenting organic material).
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